MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
The study, conducted at Monday, MIRA Pharmaceuticals Inc. (NASDAQ:MIRA) stock is trading higher with a session volume of 9.7 million compared to the average volume of 4.98 million, as per data from Benzinga Pro.
周一，MIRA制药公司（纳斯达克股票代码：MIRA）的股票交易较前一交易日的平均成交量498万上涨至970万，据Benzinga Pro数据显示。
The company announced that a recent preclinical study in rats demonstrated that its oral ketamine analog, Ketamir-2, produced a significant reversal of neuropathic pain, induced by nerve ligation, culminating in a 100% normalization of pain thresholds at the highest dose.
公司宣布最近在大鼠体内进行的一项临床前研究表明，其口服氯胺酮类似物Ketamir-2在神经结扎引起的神经病性疼痛上产生显著的逆转，最高剂量下能导致疼痛阈值100%正常化。
This effect stands in stark contrast to traditional ketamine, which proved ineffective orally under the same experimental conditions.
这个效果与传统的氯胺酮形成了鲜明对比，在相同的实验条件下口服氯胺酮表现出无效。
The study, conducted at Pharmaseed Ltd, utilized a nerve ligation model to replicate human neuropathic pain and specifically investigated mechanical allodynia.
该研究由Pharmaseed Ltd进行，利用神经结扎模型复制人类神经病性疼痛，特别调查机械性痛觉过敏。
The results showed:
研究结果显示：
- Low oral doses of Ketamir-2 led to a significant reversal of pain for 14 and 22 days following the operation.
- Ketamir-2 achieved complete normalization of the pain threshold at a higher oral dose, representing a 100% reversal of the neuropathic pain signal.
- Ketamir-2的低口服剂量导致手术后14天和22天出现疼痛显著逆转。
- Ketamir-2在更高口服剂量下实现了疼痛阈值的完全正常，代表神经病性疼痛信号的100%逆转。
These outcomes underscore Ketamir-2's superior efficacy and highlight its potential as a transformative treatment for neuropathic pain, especially compared to oral ketamine, which did not deliver significant pain relief.
这些结果突显了Ketamir-2优越的功效，并突出了其作为神经病性疼痛革新性治疗的潜力，尤其是与口服氯胺酮相比没有带来显著的缓解疼痛。
MIRA Pharmaceuticals is conducting additional studies to evaluate Ketamir-2's efficacy in treating cancer-induced depression and neuropathic pain.
MIRA制药正在进行额外研究，以评估Ketamir-2在治疗癌症引起的抑郁症和神经病理性疼痛方面的疗效。
MIRA is optimistic that these efforts could demonstrate efficacy in humans as early as 2025.
MIRA对这些努力持乐观态度，有望在2025年早期展示人类疗效。
Itzchak Angel, Chief Scientific Advisor at MIRA Pharmaceuticals, added, "The ability to administer Ketamir-2 orally without the severe psychotropic side effects commonly associated with ketamine is a remarkable achievement. This positions Ketamir-2 as a pioneering treatment in the realm of neuropathic pain, offering hope to patients who have limited options available."
MIRA制药公司的首席科学顾问Itzchak Angel补充说：“ Ketamir-2能够口服使用，而不会出现通常与氯胺酮相关的严重精神药理副作用，这是一项了不起的成就。这使Ketamir-2成为神经病理性疼痛领域的开创性治疗方法，为那些选择有限的患者带来希望。”
MIRA Pharmaceuticals continues to advance its research, focusing on scaling production and preparing for the next stages of clinical trials.
MIRA制药公司继续推进其研究工作，专注于扩大生产规模，并为下一阶段的临床试验做好准备。
In July, the company announced new insights from additional recently received preclinical study data regarding the mechanism of action and toxicology data for Ketamir-2.
该公司在七月份宣布了关于Ketamir-2的额外最新临床前研究数据，涉及药物作用机制和毒理学数据的新洞察。
Price Action: MIRA stock is up 39.4% at $2.579 during the premarket session at last check Monday.
价格行动：截至上周一最后一次检查时，MIRA股票在盘前交易中上涨39.4％，报2.579美元。
Photo via Shutterstock
图片来自shutterstock。
- Novo Nordisk Does Not Operate As Drug Cartel, CEO Defends US Pricing Of Ozempic Against Criticism Over High Drug Prices.
- 诺和诺德的首席执行官捍卫了Ozempic在美国定价方面的批评，称其并非像毒品卡特尔一样运作，遭到了高价药品的批评。
